Corey J. Langer, MD:In the last 3 to 4 months, really since the end of 2017, theEGFRmutation field has grown and has become even more complicated. There’s a major trial, called FLAURA, that was presented at the ESMO 2017 Congress. The trial directly compared osimertinib, a third-generation TKI targetingT790M, to either frontline erlotinib or gefitinib. It’s important to note that afatinib wasn’t in the control arm of this study. Osimertinib yielded a somewhat higher response rate but significantly improved progression-free survivalabout 18.9 months versus roughly 10 to 11 months in the control group.
In the minds of many of my colleagues, and to some extent myself, osimertinib has now effectively displaced gefitinib and erlotinib. It has never been directly compared with afatinib. In LUX-Lung 3, afatinib, at least in those with actionable mutations, yielded a median progression-free survival that was basically between 13 and 14 months. So, afatinib has always performed a little bit better than gefitinib and erlotinib.
This has caused some flux in the field. Afatinib still maintains an indication for treatment-naïve individuals with an actionable mutation. And, very importantly, it has an indication that is shared by none of the other agentsuse with less common mutations like exon 18 and select exon 19 mutations. I anticipate a time when we will start evaluating the results of studies that are combining angiogenesis inhibitors with TKIs. One wonders whether that combination might be equal to, or, perhaps, exceed osimertinib.
So, stay tuned. In the next 12 to 24 months, I think there will be a lot more data for individuals withEGFRmutations, and I anticipate a further improvement in their therapeutic outcomes.
Transcript edited for clarity.
June 2017
March 2018
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More